GNE-493通过准NAT10介导的HK2的ac4C修饰来抑制胃癌的发展
Tengkai Wang1, Junling Zhen2, Qingao Wei2
1Cheeloo College of Medicine, Shandong University, No. 44 Wenhua West Road, Jinan, Shandong 250012, China; Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, No. 107 Wenhua West Road, Jinan, Shandong 250012, China.
一种名为GNE-493的新药向N-乙转移酶10 (NAT10) 通过阻断葡萄糖代谢来抑制胃癌的生长. 这种方法对抗抗化学性瘤有希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 胃癌是导致消化系统恶性瘤的主要原因之一.
- 化疗抵抗使胃癌治疗复杂化,需要新的治疗策略.
- 向瘤细胞代谢重编程,包括有氧糖解,是一个有希望的方法.
研究的目的:
- 确定针对胃癌代谢的新型治疗剂.
- 调查已识别的化合物的作用机制.
- 评估化合物在耐化学药性胃癌模型中的疗效.
主要方法:
- 药物查以确定胃癌增殖抑制剂.
- 评估GNE-493对葡萄糖吸收和乳酸生产的影响.
- 调查GNE-493与NAT10的直接结合.
- 分析GNE-493对N4-乙基丁 (ac4C) 修改2 (HK2) 转录的GNE-493的影响.
- 评估GNE-493在耐思丁的胃癌细胞系中的疗效.
主要成果:
- 作为PI3K抑制剂的GNE-493有力抑制胃癌细胞的增殖.
- GNE-493通过减少葡萄糖吸收和乳酸盐生产来抑制有氧糖解.
- GNE-493直接与NAT10结合,减少HK2.2.的ac4C修改.
- 损害HK2的稳定性和翻译导致了减少的糖溶性流量.
- GNE-493对抗抗西斯普拉丁的胃癌细胞具有显著的疗效.
结论:
- GNE-493的目标是胃癌中代谢重编程的表皮转录组调节.
- 由GNE-493抑制NAT10介导的HK2乙化,抑制了瘤的进展.
- GNE-493显示出在胃癌中克服化学抵抗的潜力.
- 这一策略为高葡萄糖代谢的胃癌患者提供了一种新的治疗途径.
更多相关视频
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
05:45In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
